Lupin Ltd has launched its biosimilar ranibizumab, marketed as Ranluspec, across European markets through its commercial partner Sandoz, excluding Germany. The launch follows the European Commission’s approval of the medicine in two presentations: vials and pre-filled syringes.
The development marks an important step towards expanding access to quality biologic treatment options for patients with retinal diseases, Lupin said.
Ranluspec Approved for Multiple Retinal Conditions
Ranibizumab is used to treat several vision-threatening conditions, including neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy and choroidal neovascularisation.
The medicine is a recombinant humanised IgG1 monoclonal antibody fragment that works by binding to and inhibiting vascular endothelial growth factor A (VEGF-A). By blocking this protein, ranibizumab helps control abnormal blood vessel growth and leakage in the retina.
Lupin and Sandoz Expand Access to Biosimilar Treatment
Commenting on the launch, Thierry Volle, Lupin President, EMEA and Emerging Markets, said that introducing Ranluspec in Europe through Sandoz would help expand access to biosimilar treatment for more patients affected by retinal and choroidal vascular diseases.
The launch strengthens Lupin’s presence in the European biosimilars market while offering healthcare professionals additional treatment options for managing serious retinal conditions. As reported by The Hindu BusinessLine, Lupin’s Ranluspec has entered European markets through Sandoz following European Commission approval in vial and pre-filled syringe forms, with Germany excluded from the launch.